Cecilia Söderberg-Nauclér

Source: Wikipedia, the free encyclopedia.
Cecilia Söderberg-Nauclér
Alma materKarolinska Institute (MD)
Scientific career
InstitutionsKarolinska Institute
Thesis (1995)

Cecilia Söderberg-Nauclér, born 1967, is a

immunologist who is Professor of Microbial Pathogenesis at the Karolinska Institute. In 2013, she demonstrated that a simple antiviral could improve the life expectancy of glioblastoma disease. During the COVID-19 pandemic in Sweden, Söderberg-Nauclér on several occasions strongly criticized the Swedish response to SARS-CoV-2, claiming that they were leading the country into a catastrophe, and demanded that the Swedish state epidemiologist
should resign.

Early life and education

Her early research considered the immunogenicity of human aminopeptidase in cytomegalovirus disease.[1] Her medical career began at the Karolinska University Hospital, where she joined the Centre for Molecular Medicine in 2001.

Research and career

Söderberg-Nauclér has held a Chair in Molecular Immunology at the Karolinska Institute since 2014.[2] Her research considers human cytomegaloviruses (CMV), a family of viruses that infect between 70 and 100% of the population. In healthy patients, CMV causes no symptoms, whilst in immunosuppressed patients it can cause severe disease. Söderberg-Nauclér studies CMV in high risk patients and has developed the sensitivity of CMV detection techniques.[2] She has studied the role of CMV in inflammatory disease and cancer.[3] Söderberg-Nauclér identified that the majority of patients with rheumatism have an active CMV infection.[4]

She showed that one of CMV's

matrix metallopeptidase (MMPs) in macrophages.[4] Söderberg-Nauclér identified that CMV itself is active in different forms of cancer, including glioblastoma.[5] She compared the presence of CMV in the body tissue patients with and without glioblastoma, and showed that the virus infected 90 % of patients with glioblastoma.[6] In 2013, she identified that by treating the CMV, through an antiviral used as a supplement to oncological therapies, could extend the survival time of glioblastoma patients.[5][7] She showed that the simple antiviral treatment Valganciclovir could extend the life expectancy of glioblastoma patients by forty months.[5][8] She is leading a double-blind clinical trial to evaluate the efficacy of valganciclovir, an anti-CMV drug, in the treatment of patients with glioblastoma.[9] She has also shown that anemia can be exacerbated or induced in patients with kidney disease who have CMV.[10]

Söderberg-Nauclér criticised the response of the Swedish government to the COVID-19 pandemic in Sweden, accusing them of "leading us to catastrophe",[11][12][13] and demanded that the Swedish chief epidemiologist should resign.[14] While many other countries implemented some form of lockdown, Sweden implemented less restrictive measures, and Söderberg-Nauclér argued that they should be more strict, and impose a lockdown in Stockholm.[11][15][14] In an interview with The Guardian, Söderberg-Nauclér accused the Swedish government of "thinking they can’t stop it, so they’ve decided to let people die”.[11] Söderberg-Nauclér has in turn received criticism herself, for using inaccurate data and erroneous claims in her attacks on the Swedish authorities, including a controversial opinion piece signed by Söderberg-Nauclér along with 21 others. They later acknowledged this, but responded "as we see it, the cited numbers are less important". Söderberg-Nauclér also received criticism for sharing content criticizing the Swedish authorities from Russian state broadcaster RT.[14][16]

Selected publications

  • Hansson, Göran K.; Robertson, Anna-Karin L.; Söderberg-Nauclér, Cecilia (2006-01-24). "Inflammation and atherosclerosis". Annual Review of Pathology: Mechanisms of Disease. 1 (1): 297–329.
    PMID 18039117
    .
  • Söderberg-Nauclér, Cecilia; Fish, Kenneth N.; Nelson, Jay A. (1997-10-03). "Reactivation of Latent Human Cytomegalovirus by Allogeneic Stimulation of Blood Cells from Healthy Donors". Cell. 91 (1): 119–126.
    S2CID 11028979
    .
  • Soderberg-Naucler, C.; Streblow, D. N.; Fish, K. N.; Allan-Yorke, J.; Smith, P. P.; Nelson, J. A. (2001-08-15). "Reactivation of Latent Human Cytomegalovirus in CD14+ Monocytes Is Differentiation Dependent". Journal of Virology. 75 (16): 7543–7554.
    PMID 11462026
    .

References

  1. OCLC 186643256
    .
  2. ^ a b "Cecilia Söderberg Nauclér Group - CMM". www.cmm.ki.se. Archived from the original on 2020-06-20. Retrieved 2020-04-04.
  3. S2CID 25147713
    .
  4. ^ a b "Cecilia Söderberg-Naucler | Main". www.ceric.se. Retrieved 2020-04-04.
  5. ^ a b c "Common virus is a new target for cancer treatment". Healthcanal.com. 2013-09-05. Retrieved 2020-04-04.
  6. ^ admin (2016-05-04). "Major breakthrough in cancer research". IngaBritt och Arne Lundbergs Forskningsstiftelse. Retrieved 2020-04-04.
  7. ^ "Investigators Report Valganciclovir May Increase Survival in Glioblastoma - The ASCO Post". www.ascopost.com. Retrieved 2020-04-04.
  8. ^ "Antiviral Drug May Extend Brain Cancer Survival, Researchers Say". MedicineNet. Retrieved 2020-04-04.
  9. ^ "A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-04-04.
  10. ^ "Common virus may cause anemia in patients with kidney disease". ScienceDaily. Retrieved 2020-04-04.
  11. ^
    ISSN 0261-3077
    . Retrieved 2020-04-04.
  12. . Retrieved 2020-04-04.
  13. ^ "Coronavirus: Sweden determined it has smarter strategy for dealing with COVID-19". Radio Plymouth. Retrieved 2020-04-04.[permanent dead link]
  14. ^ a b c Svensson, Olof (15 April 2020). "Professor vill se nedstängning av Stockholm". Aftonbladet (in Swedish). Retrieved 16 April 2020.
  15. ^ "Sweden's liberal pandemic strategy questioned as Stockholm death toll mounts". Reuters. 2020-04-04. Retrieved 2020-04-04.
  16. ^ "VICTOR MALM: Coronahaveristerna är en skam för Sverige". www.expressen.se (in Swedish). Retrieved 16 April 2020.